PL2925324T3 - Trans-4-{2-[4-(2,3-dichlorofenylo)-piperazyn-1-ylo]-etylo}-N,N-dimetylokarbamoilo-cykloheksyloamina do leczenia pierwotnych objawów negatywnych schizofrenii - Google Patents

Trans-4-{2-[4-(2,3-dichlorofenylo)-piperazyn-1-ylo]-etylo}-N,N-dimetylokarbamoilo-cykloheksyloamina do leczenia pierwotnych objawów negatywnych schizofrenii

Info

Publication number
PL2925324T3
PL2925324T3 PL13805597T PL13805597T PL2925324T3 PL 2925324 T3 PL2925324 T3 PL 2925324T3 PL 13805597 T PL13805597 T PL 13805597T PL 13805597 T PL13805597 T PL 13805597T PL 2925324 T3 PL2925324 T3 PL 2925324T3
Authority
PL
Poland
Prior art keywords
dimethylcarbamoyl
cyclohexylamine
piperazin
schizophrenia
dichlorophenyl
Prior art date
Application number
PL13805597T
Other languages
English (en)
Inventor
János György PITTER
Balázs SZATMÁRI
Marc Debelle
György József NÉMETH
István Laszlovszky
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70289034&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2925324(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Publication of PL2925324T3 publication Critical patent/PL2925324T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13805597T 2012-11-29 2013-11-28 Trans-4-{2-[4-(2,3-dichlorofenylo)-piperazyn-1-ylo]-etylo}-N,N-dimetylokarbamoilo-cykloheksyloamina do leczenia pierwotnych objawów negatywnych schizofrenii PL2925324T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU1200691A HU231227B1 (hu) 2012-11-29 2012-11-29 Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
PCT/IB2013/060465 WO2014083522A1 (en) 2012-11-29 2013-11-28 Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia
EP13805597.5A EP2925324B1 (en) 2012-11-29 2013-11-28 Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating primary negative symptoms of schizophrenia

Publications (1)

Publication Number Publication Date
PL2925324T3 true PL2925324T3 (pl) 2021-06-28

Family

ID=70289034

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13805597T PL2925324T3 (pl) 2012-11-29 2013-11-28 Trans-4-{2-[4-(2,3-dichlorofenylo)-piperazyn-1-ylo]-etylo}-N,N-dimetylokarbamoilo-cykloheksyloamina do leczenia pierwotnych objawów negatywnych schizofrenii

Country Status (36)

Country Link
US (1) US20150306094A1 (pl)
EP (2) EP3653211A1 (pl)
JP (2) JP2016501215A (pl)
KR (2) KR102314248B1 (pl)
CN (1) CN104812390A (pl)
AP (1) AP2015008448A0 (pl)
AU (1) AU2013350819B9 (pl)
BR (1) BR112015012512A2 (pl)
CA (1) CA2890952A1 (pl)
CL (1) CL2015001468A1 (pl)
CR (1) CR20150244A (pl)
CY (1) CY1123766T1 (pl)
DK (1) DK2925324T3 (pl)
EA (1) EA039245B1 (pl)
ES (1) ES2863052T3 (pl)
GE (2) GEP20186849B (pl)
HR (1) HRP20210486T1 (pl)
HU (2) HU231227B1 (pl)
IL (1) IL238723B (pl)
LT (1) LT2925324T (pl)
MD (2) MD4865C1 (pl)
MX (2) MX380506B (pl)
MY (1) MY174663A (pl)
NI (1) NI201500074A (pl)
NZ (1) NZ708295A (pl)
PE (1) PE20151052A1 (pl)
PH (1) PH12015501124A1 (pl)
PL (1) PL2925324T3 (pl)
PT (1) PT2925324T (pl)
RS (1) RS61509B1 (pl)
SG (1) SG11201503672SA (pl)
SI (1) SI2925324T1 (pl)
SM (1) SMT202100149T1 (pl)
UA (1) UA123492C2 (pl)
WO (1) WO2014083522A1 (pl)
ZA (1) ZA201503660B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2975A (en) 2008-07-16 2014-09-30 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands
CN105218484B (zh) * 2015-09-14 2018-02-23 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HU231173B1 (hu) * 2016-07-08 2021-06-28 Richter Gedeon Nyrt. Ipari eljárás cariprazine előállítására
WO2019016828A1 (en) * 2017-07-15 2019-01-24 Msn Laboratories Private Limited, R&D Center NOVEL PROCESSES FOR THE PREPARATION OF TRANS-N- {4- [2- [4- (2,3-DICHLOROPHENYL) PIPERAZIN-1-YL] ETHYL] CYCLOHEXYL} -N ', N'-DIMETHYLUMED HYDROCHLORIDE AND POLYMORPHS THIS ONE
WO2019106490A1 (en) * 2017-12-01 2019-06-06 Aurobindo Pharma Limited A process for the preparation of cariprazine hydrochloride
WO2020056929A1 (zh) * 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
US11344503B2 (en) 2019-12-13 2022-05-31 Halo Science LLC Cariprazine release formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
HUP0700369A2 (en) * 2007-05-24 2009-04-28 Richter Gedeon Nyrt Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
KR20100022955A (ko) * 2007-05-24 2010-03-03 리히터 게데온 닐트. (티오) -카르바모일-시클로헥산 유도체 및 정신분열 치료 방법
WO2010126527A1 (en) * 2009-05-01 2010-11-04 Forest Laboratories Holdings Limited Methods of treating cns disorders

Also Published As

Publication number Publication date
HU231227B1 (hu) 2022-03-28
KR20210010955A (ko) 2021-01-28
MD4865C1 (ro) 2024-02-29
EP3653211A1 (en) 2020-05-20
JP2016501215A (ja) 2016-01-18
CY1123766T1 (el) 2022-05-27
UA123492C2 (uk) 2021-04-14
MD4865B1 (ro) 2023-07-31
EP2925324A1 (en) 2015-10-07
CL2015001468A1 (es) 2015-08-07
EA039245B1 (ru) 2021-12-22
KR20150088270A (ko) 2015-07-31
SI2925324T1 (sl) 2021-04-30
CA2890952A1 (en) 2014-06-05
AP2015008448A0 (en) 2015-05-31
MX2015006677A (es) 2015-08-10
AU2013350819B2 (en) 2018-05-31
EP2925324B1 (en) 2020-12-30
KR102314248B1 (ko) 2021-10-19
HUE054054T2 (hu) 2021-08-30
CN104812390A (zh) 2015-07-29
CR20150244A (es) 2015-06-23
PT2925324T (pt) 2021-02-16
AU2013350819B9 (en) 2018-06-21
PH12015501124B1 (en) 2015-08-03
IL238723A0 (en) 2015-06-30
JP2019163240A (ja) 2019-09-26
NZ708295A (en) 2020-03-27
RS61509B1 (sr) 2021-03-31
MD20200089A2 (ro) 2021-05-31
GEP20186849B (en) 2018-05-10
EA201500575A1 (ru) 2015-09-30
MX380506B (es) 2025-03-04
HK1212608A1 (en) 2016-06-17
PH12015501124A1 (en) 2015-08-03
IL238723B (en) 2020-02-27
HRP20210486T1 (hr) 2021-05-14
PE20151052A1 (es) 2015-08-09
HUP1200691A1 (pl) 2014-06-30
MX2021000342A (es) 2021-04-13
DK2925324T3 (da) 2021-03-01
SMT202100149T1 (it) 2021-07-12
NI201500074A (es) 2015-09-18
SG11201503672SA (en) 2015-06-29
WO2014083522A1 (en) 2014-06-05
ZA201503660B (en) 2016-03-30
MD20150058A2 (ro) 2015-11-30
US20150306094A1 (en) 2015-10-29
GEAP201813870A (en) 2018-01-25
ES2863052T3 (es) 2021-10-08
BR112015012512A2 (pt) 2017-07-11
MY174663A (en) 2020-05-05
AU2013350819A1 (en) 2015-06-04
LT2925324T (lt) 2021-02-25

Similar Documents

Publication Publication Date Title
IL238723A0 (en) trans-4-{2-[4-(3,2-dichlorophenyl)-piperazine-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for the treatment of negative symptoms of schizophrenia
ZA201404881B (en) Process for the manufacture of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine
CY1119105T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
EA201401054A1 (ru) N-циклиламиды в качестве нематоцидов
PL2981520T3 (pl) Nowy sposób syntezy 1-(2-((2,4-dimetylofenylo)tio)fenylo)piperazyny
HUE045452T2 (hu) Eljárás és berendezés magmentes papírtekercsek gyártására
AU2013369288A8 (en) Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
PL2608789T5 (pl) Terapeutyczne zastosowania 1-[2-(2,4- dimetylofenylosulfanylo)- fenylo]piperazyny
ME03428B (me) Postupak za proizvodnju 1-[2-(2,4-dimetil-fenilsulfanil)-fenil]-piperazina
TH148741A (th) สารประกอบที่ถูกแทนที่ด้วยฮาโลเจนชนิดใหม่